Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that includes winding down the oncology company’s Pennsylvania site and laying off 130 employees, a company spokesperson confirmed to Fierce Biotech.
https://www.fiercebiotech.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing